|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||0.7600 - 0.8299|
|52 Week Range||0.1300 - 0.8300|
|Beta (3Y Monthly)||9.18|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.00|
Humanigen, Inc., (HGEN) (“Humanigen”), a biopharmaceutical company focused on the development of its proprietary Humaneered® monoclonal antibodies to improve the safety and efficacy of chimeric antigen receptor T cell (CAR-T) therapy, announced that final results from the xenograft study of lenzilumab, a first-in-class anti-GM-CSF monoclonal antibody, were presented in the oral plenary session at the 2018 Annual Meeting of the American Society of Hematology, on Monday, December 3rd, 2018 by Rosalie Sterner from Mayo Clinic. The principal investigator for the study was Saad Kenderian, M.B., Ch.B., Mayo Clinic hematologist. The abstract entitled “GM-CSF Blockade during Chimeric Antigen Receptor T Cell Therapy Reduces Cytokine Release Syndrome and Neurotoxicity and May Enhance Their Effector Functions” was published as a first edition paper by ‘blood’® in the November 21, 2018 edition and is available online at http://www.bloodjournal.org/content/early/2018/11/21/blood-2018-10-881722. The full abstract with corresponding figures is available for review at: https://ash.confex.com/ash/2018/webprogram/Paper111766.html.
Study Demonstrates that GM-CSF Neutralization with Lenzilumab in Combination with Chimeric Antigen Receptor T (CAR-T) Cell Therapy Prevents the Onset of Cytokine Release.
DALLAS , May 22, 2018 /PRNewswire/ -- Lupagen, Inc. ( www.lupagen.com ), a medical device company developing first-in-class cell and gene therapy delivery technologies for CAR-T, gene editing and immunotherapy ...